Meningitis B type vaccine available soon
(Medical Xpress) -- Researchers in Chile have successfully tested a vaccine against meningococcus B, a strain of bacteria that causes meningococcal diseases, including one of the commonest forms of meningitis, a disease in which membranes covering the brain and spinal cord become inflamed. Meningitis can be caused by viruses or bacteria, but the bacterial forms, such as meningococcus B, are more severe and cause the deaths of many young children every year.
Neisseria meningitides is a type of bacteria that causes meningococcal disease in humans. There are five common strains: A, B, C, W135, and Y, but a sixth strain (X) has recently emerged in Africa, where it is being monitored. The new research from Chile is in the later stages of testing a vaccine, 4CMenB, for the B strain. Vaccines are already available for the A, C, W and Y strains, but the B type has been difficult to target because it is actually a collection of thousands of subtly different strains.
The scientists, from the University of Chile, overcame the difficulty of targeting the B strain by carrying out whole genome analyses and comparing the genetic structures of the various sub-strains to identify common features. These studies enabled them to develop a broad-spectrum vaccine that includes components to target four different parts of the bacterium.
The researchers tested over 1,600 adolescents aged 11-17, with an average age of 14, in a randomized trial, giving each subject either a placebo or vaccine. Those given the vaccine received one, two or three doses at intervals of one, two, or six months. The participants came from 12 sites in Chile.
Blood test results showed that almost 100% of the volunteers who received two or three doses of vaccine were protected from the meningococcus B strain, while 92-97% of those receiving only one dose of vaccine were protected. After six months these figures were 91-100% in the two or more dose groups and 73-76% in those receiving only one vaccination. It is not yet clear if the vaccine provides protection from all the sub-strains of type B, or how long the immune response will be effective. In the placebo group 29-50% had protection. None of the participants experienced harmful side effects related to the vaccine.
Previous studies by the group have shown the vaccine also provides protection for very young children. The vaccine is expected to be available from Novartis in only a few months.
Meningitis caused by the B strain is common in many European countries, in the US, and in South America.
The paper is published in the journal The Lancet. The study was funded by Novartis Vaccines and Diagnostics.
More information: Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study, The Lancet, Early Online Publication, 18 January 2012. doi:10.1016/S0140-6736(11)61713-3
Effective glycoconjugate vaccines against Neisseria meningitidis serogroups A, C, W-135, and Y have been developed, but serogroup B remains a major cause of severe invasive disease in infants and adolescents worldwide. We assessed immunogenicity and tolerability of a four-component vaccine (4CMenB) in adolescents.
We did a randomised, observer-blind, placebo-controlled, study at 12 sites in Santiago and Valparaíso, Chile. Adolescents aged 1117 years received one, two, or three doses of 4CMenB at 1 month, 2 month, or 6 month intervals. Immunogenicity was assessed as serum bactericidal activity using human complement (hSBA) against three reference strains for individual vaccine antigens, and assessed by ELISA against the fourth strain. Local and systemic reactions were recorded 7 days after each vaccination, and adverse events were monitored throughout the study. Participants were initially randomised to five groups (3:3:3:3:1) during the primary phase to receive either one dose, two doses 1 or 2 months apart, or three doses of 4CMenB, or three doses of placebo, with an additional three groups generated for the booster phase. All subjects received at least one dose of 4CMenB. Geometric mean titres, proportions of participants with serum bactericidal antibody titres of 4 or more, and Clopper-Pearson 95% CIs were calculated. The study is registered with ClinicalTrials.gov, number NCT00661713.
Overall, 1631 adolescents (mean age 13·8 [SD 1·9] years) received at least one dose of 4CMenB. After two or three doses, 99100% of recipients had hSBA titres of 4 or more against test strains, compared with 9297% after one dose (p<0·0145) and 2950% after placebo. At 6 months 91100% of participants still had titres of 4 or more for each strain after two or three doses, but only 7376% after one dose; seroresponse rates reached 99100% for each strain after second or third doses at 6 months. Local and systemic reaction rates were similar after each 4CMenB injection and did not increase with subsequent doses, but remained higher than placebo. No vaccine-related serious adverse events were reported and no significant safety signals were identified.
On the basis of immunogenicity responses this study provides evidence for an adolescent 4CMenB vaccine schedule of two doses, 16 months apart, to provide protection against meningococcal B infection. The extent of this protection against meningococcus B variants circulating worldwide will be determined by national surveys.
© 2011 Medical Xpress
- Call for further study on meningococcal vaccine Feb 14, 2007 | not rated yet | 0
- Fractional dose of scarce meningitis vaccine may be effective in outbreak control Dec 02, 2008 | not rated yet | 0
- Building a better flu vaccine: Add second strain of influenza B Apr 06, 2010 | not rated yet | 0
- FDA expands meningitis vaccine age range Oct 18, 2007 | not rated yet | 0
- Vaccinated infants well-protected against severe pneumococcal infection in Norway Jul 09, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be villous adenoma in colon, if there are no villi there
11 hours ago As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—A federal panel of medical experts says that an experimental insomnia drug from Merck & Co Inc. appears safe and effective, despite evidence from company trials that the pill can cause daytime sleepiness and difficulty ...
Medications 12 minutes ago | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications 2 hours ago | not rated yet | 0
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications 7 hours ago | not rated yet | 0
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Medications 10 hours ago | not rated yet | 0
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
2 minutes ago | not rated yet | 0
(HealthDay)—Implementation of systematic monitoring for medication adherence will allow for identification of barriers to adherence and tailoring of interventions, according to a viewpoint piece published ...
52 minutes ago | not rated yet | 0
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
52 minutes ago | not rated yet | 0
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
1 hour ago | 5 / 5 (1) | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
2 hours ago | not rated yet | 1 |
As the world prepares for what may be the next pandemic strain of influenza virus, in the H7N9 bird flu, a new UC Irvine study reveals that the 2009 H1N1 swine flu pandemic was deadliest for people under the age of 65, while ...
1 hour ago | not rated yet | 0